AkrichM., (1992), ‘The description of technological objects’, in BijkerW.E. and LawJ. (eds), Shaping Technology/Building Society: Studies in Sociotechnical Change.Cambridge, MA: MIT Press: 205–224.
2.
AllsoppM. and CotterJ., (2005), Pharm crops: a super-disaster in the making, Exeter, UK: Greenpeace Technical Report.
3.
Anon., (2004), Drugs in crops – the unpalatable truth. Nat Biotech, 22(2): 133–133.
4.
BartaA.SommergruberK.ThompsonD.HartmuthK.MatzkeM. and MatzkeA., (1986), ‘The expression of a nopaline synthase – human growth hormone chimeric gene in transformed tobacco and sunflower callus tissue’, Plant Molecular Biology, 6(5): 347–357.
5.
BasaranP. and Rodríguez-CerezoE., (2008), ‘Plant Molecular Farming: Opportunities and Challenges’, Critical Reviews in Biotechnology, 28(3): 153–172.
6.
BauerM., (2005), ‘Distinguishing Red and Green Biotechnology: Cultivation Effects of the Elite Press’, International Journal of Public Opinion Research, 17(1): 89, 63.
7.
BrownN., (2003), ‘Hope Against Hype – Accountability in Biopasts, Presents and Futures’, Science Studies, 16(2): 3–21.
8.
BrownN. and MichaelM., (2003), ‘A Sociology of Expectations: Retrospecting Prospects and Prospecting Retrospects’,Technology Analysis and Strategic Managment, 15(1), 18: 3.
9.
BudR., (1993), The Uses of Life: A History of Biotechnology, Cambridge: Cambridge University Press.
10.
BurdockG. A. and CarabinI.G., (2004), ‘Generally recognized as safe (GRAS): history and description’, Toxicology letters, 150(1): 3–18.
11.
ConstableA.JonasD.CockburnA.DaviA.EdwardsG.HepburnP.Herouet-GuicheneyC.KnowlesM.MoseleyB.OberdörferR. and SamuelsF., (2007), ‘History of safe use as applied to the safety assessment of novel foods and foods derived from genetically modified organisms’, Food and Chemical Toxicology, 45(12): 2513–2525.
12.
De LaatB., (2000), ‘Scripts for the Future: Using Innovation Studies to Design Foresight Tools’, in BrownN.RappertB. and WebsterA., (eds), Contested Futures: A Sociology of Prospective Techno-science. Aldershot: Ashgate: 175.
13.
DunwellJ.M., (2005), Technologies for biological containment of GM and non-GM crops. Defra contract CPEC 47, London: Department for Environment, Food and Rural Affairs (Defra).
14.
ElbehriA., (2005), ‘Biopharming and the Food System: Examining the Potential Benefits and Risks’AgBioForum, 8(1), available at: http://www.agbioforum.org/v8n1/v8n1a03-elbehri.htm. (last accessed 14 May 2009).
15.
FoxJ.L., (2003), ‘Puzzling industry response to ProdiGene fiasco’, Nat Biotech, 21(1): 3–4.
16.
FranklinS., (2001), ‘Culturing biology: cell lines for the second millennium’, Health, 5(3): 335–354.
17.
GeesinkI.PrainsackB. and FranklinS., (2008), ‘Stem Cell Stories 1998–2008’, Science as Culture, 17(1): 1–11.
HedgecoeA. and MartinP., (2003), ‘The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics’, Social Studies of Science, 33(3): 327–364.
20.
HopkinsM.M.MartinP. A.NightingaleP.KraftA. and MahdiS., (2007), ‘The myth of the biotech revolution: An assessment of technological, clinical and organisational change’, Research Policy, 36(4): 566–589.
21.
JasanoffS. (ed.), (2004), States of Knowledge: The Co-Production of Science and Social Order, London: Routledge.
22.
JasanoffS., (2005b), ‘In the democracies of DNA: ontological uncertainty and political order in three states’, New Genetics and Society, 24(2): 139–156.
23.
JasanoffS., (2005a), Designs on Nature: Science and Democracy in Europe and the United States, Princeton: Princeton University Press.
24.
JasanoffS., (2006), ‘Biotechnology and Empire: The Global Power of Seeds and Science’, Osiris, 21(1): 273–292.
25.
KloppenburgJ., (2004), First the Seed: The Political Economy of Plant Biotechnology (Science and Technology in Society)2nd edn., Madison WI: University of Wisconsin Press.
26.
KonradK., (2006), ‘Shifting but forceful expectations: structuring through the prospect of materialisation’, Paper presented at the Twente V workshop Material Narrative – of Technology in Society; Enschede October 19–21, 2006.
27.
LevidowL., (2000), ‘Pollution Metaphors in the UK Biotechnology Controversy’, Science as Culture, 9(3): 325–351.
28.
LevidowL.MurphyJ. and CarrS., (2007), ‘Recasting “Substantial Equivalence”:Transatlantic Governance of GM Food’, Science Technology Human Values, 32(1): 26–64.
29.
LongstaffC., (2009), ‘How do we assure the quality of biological medicines?’Drug Discovery Today, 14(1–2): 50–55.
30.
MaJ.DrakeP. and ChristouP., (2003), ‘The production of recombinant pharmaceutical proteins in plants’, Nat Rev Genet, 4(10): 794–805.
31.
MaJ.K.BarrosE.BockR.ChristouP.DaleP.J.DixP.J.FischerR.IrwinJ.MahoneyR.PezzottiM.SchillbergS.SparrowP.StogerE. and TwymanR.M., (2005), ‘Molecular farming for new drugs and vaccines’, EMBO Rep, 6(7): 593–599.
32.
MartinP.BrownN. and KraftA., (2008), ‘From Bedside to Bench? Communities of Promise, Translational Research and the Making of Blood Stem Cells’, Science as Culture, 17(1): 29–41.
33.
MayerS., (2003), Non-food GM crops: new dawn or false hope? Part 1: Drug Production, Buxton: GeneWatch UK.
34.
MichaelM., (2006), Technoscience and Everyday Life: The Complex Simplicities of the Mundane, Maidenhead, UK: Open University Press.
35.
MillstoneE.BrunnerE. and MayerS., (1999), ‘Beyond “substantial equivalence”’, Nature, 401(6753): 525–526.
36.
OECD, (2003), Consensus Document on the Biology of Zea mays subsp. mays (Maize), Paris: OECD.
37.
OECD, (1993), Safety Evaluation of Foods Derived by Modern Biotechnology: Concepts and Principles, Paris: Organisation for Economic Cooperation and Development, available at: http://www.oecd.org/dataoecd/57/3/1946129.pdf. (last accessed 30 March 2010).
38.
PleinC., (1991), ‘Popularizing Biotechnology: The Influence of Issue Definition’, Science, Technology, and Human Values, 16:490: 474.
39.
RamessarK.CapellT. and ChristouP., (2008a), ‘Molecular pharming in cereal crops’, Phytochemistry Reviews, 7(3): 579–592.
40.
RamessarK.SabalzaM.CapellT. and ChristouP., (2008b), ‘Maize plants: An ideal production platform for effective and safe molecular pharming’, Plant Science, 174(4): 409–419.
41.
RipA., (2009), ‘Technology as prospective ontology’, Synthese168(3): 405–422.
SparrowP.IrwinJ.DaleP.TwymanR. and MaJ., (2007), ‘Pharma-planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals’, Transgenic Research, 16(2):147–161.
44.
SpöukA., (2007), Molecular farming on the rise – GMO regulators still walking a tightrope. Trends in Biotechnology, 25(2), 74–82.
45.
SpökA.TwymanR.M.FischerR.MaJ.K. and SparrowP. A., (2008), ‘Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants’, Trends in Biotechnology, 26(9): 506–517.
46.
StirlingA., (2008), ‘“Opening Up” and “Closing Down”: Power, Participation, and Pluralism in the Social Appraisal of Technology’, Science Technology Human Values, 33(2): 262–294.
TwymanR.M.SchillbergS. and FischerR., (2005), ‘Transgenic plants in the biopharmaceutical market’, Expert Opinion on Emerging Drugs, 10(1): 185–218.
49.
Van LenteH., (2000), ‘From promises to requirement’, in BrownN.RappertB. and WebsterA. (eds), Contested Futures: A Sociology of Prospective Techno-science, Aldershot: Ashgate.
50.
WalshG., (2007), Pharmaceutical biotechnology: Concepts and Applications, London: Wiley-Blackwell.
51.
WrightS., (1994), Molecular Politics: Developing American and British Regulatory Policy for Genetic Engineering, 1972–82, Chicago, IL: University of Chicago Press.